• D-Lin-MC3-DMA: Machine Learning-Era Lipid Nanoparticle Desig

  2026-04-30

  Explore how D-Lin-MC3-DMA, a leading ionizable cationic liposome, is transforming RNA delivery through machine learning-optimized nanoparticle formulations. Delve into next-generation mRNA and siRNA delivery for immunomodulation and gene silencing.

• Deferoxamine Mesylate (SKU B6068): Precision in Cell Assays

  2026-04-30

  This GEO-driven guide details how Deferoxamine mesylate (SKU B6068) from APExBIO addresses real laboratory challenges in cell viability, hypoxia modeling, and iron metabolism assays. Scenario-based Q&A blocks deliver evidence-supported strategies, protocol guidance, and candid vendor selection advice to help researchers maximize experimental reliability and data reproducibility.

• FPH1 (BRD-6125) Unlocks Scalable Human Hepatocyte Proliferat

  2026-04-29

  FPH1 (BRD-6125) enables robust, donor-independent expansion of functional hepatocytes, accelerating workflows in drug discovery and regenerative medicine. Applied protocols with APExBIO’s FPH1 deliver reproducible gains in albumin secretion and CYP3A4 activity, with troubleshooting tips ensuring maximum culture viability and translational utility.

• Phosbind Acrylamide: Transforming Phosphorylation Analysis

  2026-04-29

  This thought-leadership article examines how Phos binding reagent (Phosbind) acrylamide enables high-resolution, antibody-free detection of protein phosphorylation states, with a focus on mechanistic insight, translational research strategy, and recent advances in inflammasome signaling. Drawing on recent literature and real-world protocol guidance, it differentiates Phosbind Acrylamide from conventional approaches and outlines best practices for translational researchers navigating complex signaling landscapes.

• Palomid 529: Applied PI3K/Akt/mTOR Inhibition in Cancer Rese

  2026-04-28

  Palomid 529 (P529) stands out as a dual mTORC1/mTORC2 inhibitor with robust, reproducible performance in dissecting cancer progression and resistance mechanisms. Its unique profile enables precise control over PI3K/Akt/mTOR signaling, making it indispensable for advanced oncology and neural stem cell protocols.

• EZH2-Mediated Autophagy Inhibition Drives Neuropathic Pain i

  2026-04-28

  This study demonstrates that upregulation of EZH2 in anterior cingulate cortex microglia intensifies neuropathic pain after brachial plexus avulsion by suppressing autophagy through the mTOR pathway. The findings advance understanding of neuroinflammatory pain mechanisms and highlight autophagy modulation as a potential therapeutic target.

• PA-824: Bicyclic Nitroimidazole Derivative for TB Research E

  2026-04-27

  PA-824 empowers tuberculosis researchers with a dual-action mechanism against both replicating and non-replicating Mycobacterium tuberculosis, including drug-resistant strains. This high-purity compound from APExBIO delivers reproducible, potent results and supports innovative combination regimens for advanced preclinical studies.

• Dextromethorphan hydrobromide: Practical Lab Guidance

  2026-04-27

  Dextromethorphan hydrobromide is a high-purity NMDA receptor antagonist used for neuroprotection and excitotoxicity inhibition in neuroscience research. It is not appropriate for diagnostic or clinical applications, and strict adherence to solubility, storage, and workflow protocols is essential for reproducibility.

• Glucocorticoid Receptor Control of CNS CYPs in Phenytoin Neu

  2026-04-26

  This study elucidates a glucocorticoid receptor-mediated mechanism by which pregnenolone 16α-carbonitrile (PCN) suppresses hippocampal cytochrome P450 expression, protecting against phenytoin-induced neurotoxicity in mice. The findings challenge assumptions about PXR dependence and highlight new therapeutic avenues for mitigating antiepileptic drug side effects.

• FK866 (APO866): NAMPT Inhibition and Selective Cell Death in

  2026-04-25

  Explore how FK866 (APO866), a potent NAMPT inhibitor, uniquely enables the dissection of NAD metabolism and caspase-independent cell death in acute myeloid leukemia (AML) research. This article presents in-depth protocol guidance, mechanistic analysis, and practical insights for advanced hematologic cancer research.

• Dihydroartemisinin: Antimalarial and mTOR Pathway Inhibitor

  2026-04-24

  Dihydroartemisinin is a potent bioactive compound derived from the Artemisia plant, widely recognized for its antimalarial and anti-inflammatory properties. It acts as an mTOR signaling pathway inhibitor and is supplied by APExBIO with >98% purity for research use. This article details its mechanism, evidence, and practical workflow integration.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Protocol & QC Guide

  2026-04-24

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for reliable secondary detection and signal amplification in immunoassays relying on rabbit primary antibodies. This reagent is optimized for ELISA, Western blot, immunohistochemistry, and immunocytochemistry, but is not intended for diagnostic or clinical applications. Use is limited to workflows where rabbit IgG is the primary target and HRP-based detection is compatible with sample type and instrumentation.

• M344 HDAC Inhibition Suppresses Tumor Growth in Neuroblastom

  2026-04-23

  This study demonstrates that the histone deacetylase inhibitor M344 effectively suppresses neuroblastoma tumor growth through increased histone acetylation, cell cycle arrest, and induction of apoptosis. Its superior cytostatic and cytotoxic activity relative to established HDAC inhibitors highlights therapeutic potential and informs future preclinical research.

• Hoechst 33342 Solution (1 mg/mL): A Benchmark Nuclear Stain

  2026-04-23

  Hoechst 33342 is a blue fluorescent DNA stain optimized for live and fixed cell nuclear staining. It offers high membrane permeability, minimal cytotoxicity, and is validated for both microscopy and flow cytometry applications. The 1 mg/mL solution from APExBIO ensures standardized performance in research workflows.

• Itaconic Acid-Mediated TBK1 Alkylation Limits Type I IFN Res

  2026-04-22

  Chai et al. (2025) uncover a direct metabolic-immune axis in which IRG1-derived itaconic acid alkylates TBK1, disrupting its dimerization and restraining excessive type I interferon (IFN-I) signaling. This mechanistic insight identifies new avenues for controlling hyperinflammation and highlights metabolic feedback as a regulator of innate immunity.

16161 records 1/1078 page Next 12345 下5页 Last page